Chapter 7 Paclitaxel.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Profiles of Drug Substances, Excipients and Related Methodology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S1871-5125(09)34007-8PMID 22469177
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Taxoids

  2012cited by this paper
• BMC Clinical Pharmacology BioMed Central

  2007cited by this paper
• A mucoadhesive in situ gel delivery system for paclitaxel

  2006cited by this paper
• High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection

  2006cited by this paper
• Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes.

  2006cited by this paper
• Association of Paclitaxel Pharmacokinetics with the Development of Peripheral Neuropathy in Patients with Advanced Cancer

  2005cited by this paper
• Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer.

  2005cited by this paper
• βIII-Tubulin Induces Paclitaxel Resistance in Association with Reduced Effects on Microtubule Dynamic Instability*

  2005cited by this paper
• In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of Paclitaxel: gel, film, prodrug, liposomes and micelles.

  2005cited by this paper
• Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.

  2005cited by this paper
• NMR characterization of paclitaxel/poly (styrene-isobutylene-styrene) formulations.

  2005cited by this paper
• Sensitive HPLC method for quantitation of paclitaxel (Genexol in biological samples with application to preclinical pharmacokinetics and biodistribution.

  2005cited by this paper
• The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation.

  2004cited by this paper
• Paclitaxel: as adjuvant or neoadjuvant therapy in early breast cancer.

  2004cited by this paper
• Tumor-specific novel taxoid-monoclonal antibody conjugates.

  2004cited by this paper
• The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study

  2004cited by this paper
• A phase II trial of paclitaxel (Taxol®) as first line treatment in advanced breast cancer

  2004cited by this paper
• Do multiple cytochrome P450 isoforms contribute to parathion metabolism in man?

  2003cited by this paper
• Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma.

  2003cited by this paper
• Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-beta-lactamase fusion protein.

  2003cited by this paper
• Antitumor agents 216. Synthesis and evaluation of paclitaxel-camptothecin conjugates as novel cytotoxic agents.

  2003cited by this paper
• Measurement of paclitaxel in biological matrices: high-throughput liquid chromatographic-tandem mass spectrometric quantification of paclitaxel and metabolites in human and dog plasma.

  2003cited by this paper
• Quantitation of paclitaxel in micro-sample rat plasma by a sensitive reversed-phase HPLC assay.

  2003cited by this paper
• Preparation, characterization, molecular modeling and in vitro activity of paclitaxel-cyclodextrin complexes.

  2002cited by this paper
• Paclitaxel and its formulations.

  2002cited by this paper
• Tumor specific novel taxoid-monoclonal antibody conjugates.

  2002cited by this paper
• Synthesis of C-3' methyl taxotere (docetaxel).

  2002cited by this paper
• Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics.

  2002cited by this paper
• Reductively activated disulfide prodrugs of paclitaxel.

  2002cited by this paper
• Hydrolyzable hydrophobic taxanes: synthesis and anti-cancer activities

  2001cited by this paper
• Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity.

  2001cited by this paper
• Potentiation of radioresponse by polymer-drug conjugates.

  2001cited by this paper
• Drug interactions with the taxanes: clinical implications.

  2001cited by this paper
• Antitumor agents 210. Synthesis and evaluation of taxoid-epipodophyllotoxin conjugates as novel cytotoxic agents.

  2001cited by this paper
• Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers.

  2001cited by this paper
• Regional drug delivery with radiation for the treatment of Ewing's sarcoma. In vitro development of a taxol release system.

  2001cited by this paper
• Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics.

  2001cited by this paper
• Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI‐007)

  2001cited by this paper
• Use of an Isolated Joint Model to Detect Early Changes Induced by Intra-Articular Injection of Paclitaxel-Impregnated Polymeric Microspheres

  2001cited by this paper
• Controlled delivery of taxol from poly(ethylene glycol)-coated poly(lactic acid) microspheres.

  2001cited by this paper
• Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

  2001cited by this paper
• Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds.

  2000cited by this paper
• A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells.

  2000cited by this paper
• Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel.

  2000cited by this paper
• Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.

  2000cited by this paper
• Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography.

  1999cited by this paper
• Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin.

  1998cited by this paper
• Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.

  1998cited by this paper
• Camptothecin and taxol: Discovery to clinic

  1998cited by this paper
• Design and synthesis of a water-soluble taxol analogue: taxol-sialyl conjugate.

  1998cited by this paper
• Pharmaceutical aspects of paclitaxel

  1998cited by this paper
• Cellular uptake profile of paclitaxel using liquid chromatography tandem mass spectrometry.

  1998cited by this paper
• Patient preferences for oral versus intravenous palliative chemotherapy.

  1997cited by this paper
• Solid-state characterization of paclitaxel.

  1997cited by this paper
• Release of taxol from poly(ϵ-caprolactone) pastes: effect of water-soluble additives

  1997cited by this paper
• A simple and reliable reverse-phase high-performance liquid chromatographic procedure for determination of paclitaxel (taxol) in human serum.

  1997cited by this paper
• Protective effect of liposome encapsulation on paclitaxel developmental toxicity in the rat.

  1997cited by this paper
• The development of a novel intraperitoneal tumor-seeding prophylactic.

  1997cited by this paper
• The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs.

  1996cited by this paper
• Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer.

  1996cited by this paper
• Single agent paclitaxel in advanced squamous cell head and neck carcinoma.

  1996cited by this paper
• Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

  1996cited by this paper
• Camptothecin and taxol: from discovery to clinic.

  1996cited by this paper
• Methyl jasmonate-induced overproduction of paclitaxel and baccatin III in Taxus cell suspension cultures

  1996cited by this paper
• Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy.

  1996cited by this paper
• Development of a Polymeric Surgical Paste Formulation for Taxol

  1996cited by this paper
• A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines.

  1996cited by this paper
• Total Synthesis of Baccatin III and Taxol

  1996cited by this paper
• Taxol production in nodule cultures of Taxus.

  1996cited by this paper
• Pharmacokinetic study of taxol-loaded poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate after targeted delivery to the lung in mice.

  1996cited by this paper
• Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol.

  1996cited by this paper
• Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer.

  1996cited by this paper
• Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.

  1996cited by this paper
• Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture.

  1995cited by this paper
• Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.

  1995cited by this paper
• Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.

  1995cited by this paper
• Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins.

  1995cited by this paper
• Isocratic high-performance liquid chromatographic assay of taxol in biological fluids and tissues using automated column switching.

  1995cited by this paper
• Antitumor Efficacy of Taxane Liposomes on a Human Ovarian Tumor Xenograft in Nude Mice

  1995cited by this paper
• Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.

  1995cited by this paper
• Paclitaxel in cancer treatment

  1995cited by this paper
• A New Large-Scale Process for Taxol and Related Taxanes from Taxusbrevifolia

  1995cited by this paper
• Paclitaxel (taxol)

  1995cited by this paper
• Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

  1995cited by this paper
• Crystal and molecular structure of paclitaxel (taxol).

  1995cited by this paper
• Expedient Liquid Chromatographic Assay for Paclitaxel in Plasma After Its Administration to Cancer Patients

  1995cited by this paper
• Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer.

  1995cited by this paper
• Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

  1995cited by this paper
• High-performance liquid chromatographic procedures for the quantitative determination of paclitaxel (Taxol) in human urine.

  1995cited by this paper
• Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.

  1995cited by this paper
• 345 A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)

  1995cited by this paper
• Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid).

  1995cited by this paper
• New bioactive taxoids from cell cultures of Taxus baccata.

  1994cited by this paper
• Biodegradable long-circulating polymeric nanospheres.

  1994cited by this paper
• Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation.

  1994cited by this paper
• Synthesis of Novel Taxoids

  1994cited by this paper
• First total synthesis of taxol. 2. Completion of the C and D rings

  1994cited by this paper
• First total synthesis of taxol. 1. Functionalization of the B ring

  1994cited by this paper
• Pharmaceutical issues of paclitaxel.

  1994cited by this paper
• Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

  1994cited by this paper

• Amphiphilic Polypeptides Obtained by Post-Polymerization Modification of Poly-l-Lysine as Systems for Combined Delivery of Paclitaxel and siRNA

  2023cites this paper
• Theranostic polymeric nanoparticles as a new approach in cancer therapy and diagnosis: a review

  2023cites this paper
• Amphiphilic Polypeptides Obtained by the Post-Polymerization Modification of Poly(Glutamic Acid) and Their Evaluation as Delivery Systems for Hydrophobic Drugs

  2023cites this paper
• Recent Development of Nano-Carbon Material in Pharmaceutical Application: A Review

  2022cites this paper
• LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack.

  2021cites this paper
• Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

  2021cites this paper
• Andrographis paniculata (Burm. F.) Wall. Ex Nees, Andrographolide, and Andrographolide Analogues as SARS-CoV-2 Antivirals? A Rapid Review

  2021cites this paper
• Self-Assembled Nanoparticles Based on Block-Copolymers of Poly(2-Deoxy-2-methacrylamido-d-glucose)/Poly(N-Vinyl Succinamic Acid) with Poly(O-Cholesteryl Methacrylate) for Delivery of Hydrophobic Drugs

  2021cites this paper
• Utilization of novel self-nanoemulsifying formulations (SNEFs) loaded paclitaxel for the treatment prosperity of bladder cancer

  2020influential citation
• Taxus brevifolia (Pacific Yew)

  2020cites this paper
• Singlet oxygen-activatable Paclitaxel prodrugs via intermolecular activation for combined PDT and chemotherapy.

  2019cites this paper
• Development and validation of the HPLC method for simultaneous estimation of Paclitaxel and topotecan.

  2014cites this paper
• Nanomedicine I: In vitro and in vivo evaluation of paclitaxel loaded poly-(ε-caprolactone), poly (dl-lactide-co-glycolide) and poly (dl-lactic acid) matrix nanoparticles in wistar rats

  2014cites this paper
• Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges.

  2009cites this paper